ABC | Volume 113, Nº2, Agosto 2019

Artigo Original Yan et al. O efeito da Lipoproteína na insuficiência cardíaca crônica Arq Bras Cardiol. 2019; 113(2):197-204 11. Erqou S, Thompson A, Di AE, Saleheen D, Kaptoge S, Marcovina S, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J AmColl Cardiol. 2010; 55(19):2160-7. 12. Schmidt K, Noureen A, Kronenberg F, UtermannG. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016; 57(8):1339-59. 13. van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation. 2016; 134(8):611-24. 14. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) andmechanismof inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003; 278(26):23260-9. 15. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004; 24(12):2219-26. 16. Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG, et al. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J Am Coll Cardiol. 2015; 66(11):1236-1246. 17. Kamstrup PR, Nordestgaard BG. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. JACC Heart Fail. 2016; 4(1):78-87. 18. Ponikowski P, Voors AA, Anker SD, BuenoH, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8):891-975. 19. AlbertiKG,ZimmetPZ.Definition,diagnosisandclassificationofdiabetesmellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisionalreportofaWHOconsultation.DiabetMed.1998;15(7):539-53. 20. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17(10):2937-44. 21. Mitsuda T, Uemura Y, Ishii H, Takemoto K, Uchikawa T, Koyasu M, et al. Lipoprotein(a) levels predict adverse vascular events after acutemyocardial infarction. Heart Vessels. 2016; 31(12):1923-9. 22. Feng Z, Li HL, Bei WJ, Guo XS, Wang K, Yi SX, et al. Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention. Clin Cardiol. 2017; 40(9):674-678. 23. Feng Z, Li HL, Bei WJ, Guo XS, Wang K, Yi SX. Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention. Clin Cardiol. 2017; 40(9):674-8. 24. MartiCN,GheorghiadeM,KalogeropoulosAP,GeorgiopoulouVV,Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012; 60(16):1455-69. 25. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-53. 26. Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007; 71(10):1036-43. 27. Nicholls SJ, TangWH, Scoffone H, Brennan DM, Hartiala J, Allayee H, et al. Lipoprotein(a) levels and long-termcardiovascular risk in the contemporary era of statin therapy. J Lipid Res. 2010; 51(10):3055-61. 28. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMGCoAreductase inhibitors lowerLDLcholesterolwithoutreducingLp(a) levels. Circulation. 1989; 80(5):1313-9. 29. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010; 126(3):314-45. 30. Cooper DL, Murrell DE, Roane DS, Harirforoosh S. Effects of formulation design on niacin therapeutics: mechanismof action, metabolism, and drug delivery. Int J Pharm. 2015; 490(1-2):55-64. 31. Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015; 35(3):689-99. 32. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1489-99. Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 204